biotech

biotech Articles

Gilead Sciences Inc. (NASDAQ: GILD) released third-quarter earnings report after markets closed on Tuesday. Despite negative news coming out on Tuesday with former presidential candidate Bernie...
Although Gilead has been falling for about a year now, the valuation is looking more favorable — assuming Gilead is not a value trap. The earnings report will help shed some light on where the...
Shares of InspireMD more than doubled in Tuesday’s session after the company announced followup data from its Paradigm-101 trial of the CGuard Embolic Prevention System.
Ophthotech Corp. (NASDAQ: OPHT) is watching its shares rise in Monday’s trading session after the company reported results from its mid-stage trial of Fovista in combination with Lucentis for the...
Shares of Ariad Pharmaceuticals saw a modest gain early Monday after the company announced a recent FDA decision.
Genocea Biosciences shares saw a handy gain early Friday following the release of mid-stage results from its genital herpes treatment.
Opexa Therapeutics Inc. (NASDAQ: OPXA) shares were in free fall Friday morning after the company reported results from its mid-stage trial for the treatment of secondary progressive multiple...
Though Amgen reported better-than-expected third-quarter results on Thursday, shares sank early Friday.
Biotech giant Amgen is scheduled to release its third-quarter financial results after the markets close on Thursday.
Myovant Sciences entered the market near the high end of its expected price range for its initial public offering.
Shares of ProQR Therapeutics jumped early on Thursday after the company announced results from its cystic fibrosis study.
Biogen reported better-than-expected third-quarter financial results before the markets opened on Wednesday,
The October 14 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Myovant Sciences registered an amended Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price 13 million shares in...
Ariad Pharmaceuticals shares were down handily on Monday after JPMorgan downgraded the stock. Also Senator Sanders recently asked about the pricing of its blood cancer drug Iclusig.